The Role of PET/CT with {sup 18}F-FDG in the Assessment of Therapeutic Response of Head and Neck Cancer
Purpose of Review: To make a brief review on the pre-treatment evaluation of head and neck squamous cell carcinoma (HNSCC) with positron emission tomography/computed tomography with 18F-Fluoro-deoxy-glucose ({sup 18}F-FDG PET/CT) and to discuss the use of this method after treatment, with emphasis o...
Gespeichert in:
| Veröffentlicht in: | Current radiology reports (Philadelphia, PA ) PA ), 2018-02, Vol.6 (2) |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | |
| container_title | Current radiology reports (Philadelphia, PA ) |
| container_volume | 6 |
| creator | Alves, Wilson Eduardo Furlan Matos Pitella, Felipe Arriva Rocha, Euclides Timoteo da Wichert-Ana, Lauro |
| description | Purpose of Review: To make a brief review on the pre-treatment evaluation of head and neck squamous cell carcinoma (HNSCC) with positron emission tomography/computed tomography with 18F-Fluoro-deoxy-glucose ({sup 18}F-FDG PET/CT) and to discuss the use of this method after treatment, with emphasis on the evaluation of therapeutic response. Recent Findings: The {sup 18}F-FDG PET/CT pre-treatment evaluation is recommended at III–IV staging to determine metastasis foci. At post-evaluation, the use of {sup 18}F-FDG PET/CT is very important to confirm the therapeutic response based on its high negative predictive value (NPV), mostly when it is made after 12 weeks the last radiotherapy dose. Specific imaging criteria aid in the detection of active tumor lesions. Moreover, the {sup 18}F-FDG PET/CT can determine early failure treatment and overall survival and progression-free survival. Recently, the {sup 18}F-FDG PET/CT surveillance was showed an important tool to follow up HNSCC patients with stage N2 or N3 disease. Summary: The {sup 18}F-FDG PET/CT is essential in the management of HNSCC, mainly at post-treatment evaluation. Its findings can determine a complementary therapy or even avoid an aggressive and unnecessary approach. So, careful analysis using imaging interpretation criteria has been central to an accurate assessment of HNSCC patients. |
| doi_str_mv | 10.1007/s40134-018-0264-x |
| format | Article |
| fullrecord | <record><control><sourceid>osti</sourceid><recordid>TN_cdi_osti_scitechconnect_22876207</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22876207</sourcerecordid><originalsourceid>FETCH-LOGICAL-o98t-a8af9e96b6a2c06aa394cd5d67c5e07ad0b93b749072bdb22142f142927915db3</originalsourceid><addsrcrecordid>eNpNjE1LAzEYhIMoWGp_gLeA59gkm83Hsaz9EESl7L1kk3ftas2WvikK4n93_Tg4MMwc5hlCLgW_FpybKSouCsW4sIxLrdj7CRlJoQ1TVpan__o5mSA-80F24LQYkad6C3Td74D2LX2c19Oqpm9d3tIPPO6psJ8LtrhZ0i7RPAxniID4Cil_zwf04PdwzF2ga8B9n_DnZgU-Up8ivYfwQiufAhwuyFnrdwiTvxyTejGvqxW7e1jeVrM71jubmbe-deB0o70MXHtfOBViGbUJJXDjI29c0RjluJFNbKQUSraDnTROlLEpxuTq97bH3G0wdBnCNvQpQcgbKa3RkpviCxueV5k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Role of PET/CT with {sup 18}F-FDG in the Assessment of Therapeutic Response of Head and Neck Cancer</title><source>SpringerLink Journals</source><creator>Alves, Wilson Eduardo Furlan Matos ; Pitella, Felipe Arriva ; Rocha, Euclides Timoteo da ; Wichert-Ana, Lauro</creator><creatorcontrib>Alves, Wilson Eduardo Furlan Matos ; Pitella, Felipe Arriva ; Rocha, Euclides Timoteo da ; Wichert-Ana, Lauro</creatorcontrib><description>Purpose of Review: To make a brief review on the pre-treatment evaluation of head and neck squamous cell carcinoma (HNSCC) with positron emission tomography/computed tomography with 18F-Fluoro-deoxy-glucose ({sup 18}F-FDG PET/CT) and to discuss the use of this method after treatment, with emphasis on the evaluation of therapeutic response. Recent Findings: The {sup 18}F-FDG PET/CT pre-treatment evaluation is recommended at III–IV staging to determine metastasis foci. At post-evaluation, the use of {sup 18}F-FDG PET/CT is very important to confirm the therapeutic response based on its high negative predictive value (NPV), mostly when it is made after 12 weeks the last radiotherapy dose. Specific imaging criteria aid in the detection of active tumor lesions. Moreover, the {sup 18}F-FDG PET/CT can determine early failure treatment and overall survival and progression-free survival. Recently, the {sup 18}F-FDG PET/CT surveillance was showed an important tool to follow up HNSCC patients with stage N2 or N3 disease. Summary: The {sup 18}F-FDG PET/CT is essential in the management of HNSCC, mainly at post-treatment evaluation. Its findings can determine a complementary therapy or even avoid an aggressive and unnecessary approach. So, careful analysis using imaging interpretation criteria has been central to an accurate assessment of HNSCC patients.</description><identifier>ISSN: 2167-4825</identifier><identifier>EISSN: 2167-4825</identifier><identifier>DOI: 10.1007/s40134-018-0264-x</identifier><language>eng</language><publisher>United States</publisher><subject>CARCINOMAS ; EVALUATION ; FLUORINE 18 ; GLUCOSE ; HEAD ; MEDICAL SURVEILLANCE ; METASTASES ; MONITORING ; NECK ; PATIENTS ; POSITRON COMPUTED TOMOGRAPHY ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; SECURITY ; THERAPEUTIC DOSES</subject><ispartof>Current radiology reports (Philadelphia, PA ), 2018-02, Vol.6 (2)</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.osti.gov/biblio/22876207$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Alves, Wilson Eduardo Furlan Matos</creatorcontrib><creatorcontrib>Pitella, Felipe Arriva</creatorcontrib><creatorcontrib>Rocha, Euclides Timoteo da</creatorcontrib><creatorcontrib>Wichert-Ana, Lauro</creatorcontrib><title>The Role of PET/CT with {sup 18}F-FDG in the Assessment of Therapeutic Response of Head and Neck Cancer</title><title>Current radiology reports (Philadelphia, PA )</title><description>Purpose of Review: To make a brief review on the pre-treatment evaluation of head and neck squamous cell carcinoma (HNSCC) with positron emission tomography/computed tomography with 18F-Fluoro-deoxy-glucose ({sup 18}F-FDG PET/CT) and to discuss the use of this method after treatment, with emphasis on the evaluation of therapeutic response. Recent Findings: The {sup 18}F-FDG PET/CT pre-treatment evaluation is recommended at III–IV staging to determine metastasis foci. At post-evaluation, the use of {sup 18}F-FDG PET/CT is very important to confirm the therapeutic response based on its high negative predictive value (NPV), mostly when it is made after 12 weeks the last radiotherapy dose. Specific imaging criteria aid in the detection of active tumor lesions. Moreover, the {sup 18}F-FDG PET/CT can determine early failure treatment and overall survival and progression-free survival. Recently, the {sup 18}F-FDG PET/CT surveillance was showed an important tool to follow up HNSCC patients with stage N2 or N3 disease. Summary: The {sup 18}F-FDG PET/CT is essential in the management of HNSCC, mainly at post-treatment evaluation. Its findings can determine a complementary therapy or even avoid an aggressive and unnecessary approach. So, careful analysis using imaging interpretation criteria has been central to an accurate assessment of HNSCC patients.</description><subject>CARCINOMAS</subject><subject>EVALUATION</subject><subject>FLUORINE 18</subject><subject>GLUCOSE</subject><subject>HEAD</subject><subject>MEDICAL SURVEILLANCE</subject><subject>METASTASES</subject><subject>MONITORING</subject><subject>NECK</subject><subject>PATIENTS</subject><subject>POSITRON COMPUTED TOMOGRAPHY</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>SECURITY</subject><subject>THERAPEUTIC DOSES</subject><issn>2167-4825</issn><issn>2167-4825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpNjE1LAzEYhIMoWGp_gLeA59gkm83Hsaz9EESl7L1kk3ftas2WvikK4n93_Tg4MMwc5hlCLgW_FpybKSouCsW4sIxLrdj7CRlJoQ1TVpan__o5mSA-80F24LQYkad6C3Td74D2LX2c19Oqpm9d3tIPPO6psJ8LtrhZ0i7RPAxniID4Cil_zwf04PdwzF2ga8B9n_DnZgU-Up8ivYfwQiufAhwuyFnrdwiTvxyTejGvqxW7e1jeVrM71jubmbe-deB0o70MXHtfOBViGbUJJXDjI29c0RjluJFNbKQUSraDnTROlLEpxuTq97bH3G0wdBnCNvQpQcgbKa3RkpviCxueV5k</recordid><startdate>20180215</startdate><enddate>20180215</enddate><creator>Alves, Wilson Eduardo Furlan Matos</creator><creator>Pitella, Felipe Arriva</creator><creator>Rocha, Euclides Timoteo da</creator><creator>Wichert-Ana, Lauro</creator><scope>OTOTI</scope></search><sort><creationdate>20180215</creationdate><title>The Role of PET/CT with {sup 18}F-FDG in the Assessment of Therapeutic Response of Head and Neck Cancer</title><author>Alves, Wilson Eduardo Furlan Matos ; Pitella, Felipe Arriva ; Rocha, Euclides Timoteo da ; Wichert-Ana, Lauro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-o98t-a8af9e96b6a2c06aa394cd5d67c5e07ad0b93b749072bdb22142f142927915db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>CARCINOMAS</topic><topic>EVALUATION</topic><topic>FLUORINE 18</topic><topic>GLUCOSE</topic><topic>HEAD</topic><topic>MEDICAL SURVEILLANCE</topic><topic>METASTASES</topic><topic>MONITORING</topic><topic>NECK</topic><topic>PATIENTS</topic><topic>POSITRON COMPUTED TOMOGRAPHY</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>SECURITY</topic><topic>THERAPEUTIC DOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Alves, Wilson Eduardo Furlan Matos</creatorcontrib><creatorcontrib>Pitella, Felipe Arriva</creatorcontrib><creatorcontrib>Rocha, Euclides Timoteo da</creatorcontrib><creatorcontrib>Wichert-Ana, Lauro</creatorcontrib><collection>OSTI.GOV</collection><jtitle>Current radiology reports (Philadelphia, PA )</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alves, Wilson Eduardo Furlan Matos</au><au>Pitella, Felipe Arriva</au><au>Rocha, Euclides Timoteo da</au><au>Wichert-Ana, Lauro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of PET/CT with {sup 18}F-FDG in the Assessment of Therapeutic Response of Head and Neck Cancer</atitle><jtitle>Current radiology reports (Philadelphia, PA )</jtitle><date>2018-02-15</date><risdate>2018</risdate><volume>6</volume><issue>2</issue><issn>2167-4825</issn><eissn>2167-4825</eissn><abstract>Purpose of Review: To make a brief review on the pre-treatment evaluation of head and neck squamous cell carcinoma (HNSCC) with positron emission tomography/computed tomography with 18F-Fluoro-deoxy-glucose ({sup 18}F-FDG PET/CT) and to discuss the use of this method after treatment, with emphasis on the evaluation of therapeutic response. Recent Findings: The {sup 18}F-FDG PET/CT pre-treatment evaluation is recommended at III–IV staging to determine metastasis foci. At post-evaluation, the use of {sup 18}F-FDG PET/CT is very important to confirm the therapeutic response based on its high negative predictive value (NPV), mostly when it is made after 12 weeks the last radiotherapy dose. Specific imaging criteria aid in the detection of active tumor lesions. Moreover, the {sup 18}F-FDG PET/CT can determine early failure treatment and overall survival and progression-free survival. Recently, the {sup 18}F-FDG PET/CT surveillance was showed an important tool to follow up HNSCC patients with stage N2 or N3 disease. Summary: The {sup 18}F-FDG PET/CT is essential in the management of HNSCC, mainly at post-treatment evaluation. Its findings can determine a complementary therapy or even avoid an aggressive and unnecessary approach. So, careful analysis using imaging interpretation criteria has been central to an accurate assessment of HNSCC patients.</abstract><cop>United States</cop><doi>10.1007/s40134-018-0264-x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2167-4825 |
| ispartof | Current radiology reports (Philadelphia, PA ), 2018-02, Vol.6 (2) |
| issn | 2167-4825 2167-4825 |
| language | eng |
| recordid | cdi_osti_scitechconnect_22876207 |
| source | SpringerLink Journals |
| subjects | CARCINOMAS EVALUATION FLUORINE 18 GLUCOSE HEAD MEDICAL SURVEILLANCE METASTASES MONITORING NECK PATIENTS POSITRON COMPUTED TOMOGRAPHY RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY SECURITY THERAPEUTIC DOSES |
| title | The Role of PET/CT with {sup 18}F-FDG in the Assessment of Therapeutic Response of Head and Neck Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A19%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-osti&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20PET/CT%20with%20%7Bsup%2018%7DF-FDG%20in%20the%20Assessment%20of%20Therapeutic%20Response%20of%20Head%20and%20Neck%20Cancer&rft.jtitle=Current%20radiology%20reports%20(Philadelphia,%20PA%20)&rft.au=Alves,%20Wilson%20Eduardo%20Furlan%20Matos&rft.date=2018-02-15&rft.volume=6&rft.issue=2&rft.issn=2167-4825&rft.eissn=2167-4825&rft_id=info:doi/10.1007/s40134-018-0264-x&rft_dat=%3Costi%3E22876207%3C/osti%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |